Rupak Doshi

Rupak Doshi has a diverse and extensive work experience, beginning in 2006 with a Trainee Research Assistant position at Sun Pharmaceutical Industries Ltd. In 2007, they took on a Translational Medicine Student role at The University of Manchester. In 2008, they became a Grad Student at The University of Cambridge. From 2012 to 2013, they were a Postdoctoral Research Associate at The Scripps Research Institute. In 2013, they became a Project Scientist at University of California, San Diego. In 2017, they took on a Project Scientist (P/T) role at UC Irvine. In 2016, they became a Research Scientist at InhibRx. Most recently, in 2019, they assumed the role of Co-Founder & CEO of OmniSync.

Rupak Doshi's education history includes a Doctor of Philosophy (PhD) in Pharmacology & Biochemistry from the University of Cambridge (2008-2011), a Master of Research (MRes) in Translational Medicine from The University of Manchester (2007-2008), a Bachelor of Science (BSc) in Biotechnology from Vellore Institute of Technology (2003-2006), and secondary school from St. James' School, Kolkata (1990-2003).